Eisai loses DEA battle

Share this article:

Eisai's legal maneuver to pressure the DEA to schedule its FDA-approved epilepsy drug has failed. BioCentury reports that the District of Columbia's US Court of Appeals will not compel the Drug Enforcement Agency to put the seizure medication, Fycompa, on a schedule within a given time frame.

Without a designated schedule, Eisai cannot put the drug on the market, even though the patent life continues to wind down.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.